October 13, 2022
Obsidian Therapeutics to Present at Upcoming Scientific Conferences
Obsidian team to discuss novel manufacturing and engineering approaches to TIL therapy for enhancing anti-tumor activity
CAMBRIDGE, Mass., October 13, 2022 – Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced that the company will attend and present in the following upcoming scientific conferences in which key thought leaders will gather to discuss cutting-edge advances in cell therapies.
Process Development for Cell Therapy Summit, October 18-20, 2022, Woburn, MA
Katie Aron, Ph.D., Director of Process Development at Obsidian, will present the case study “Discussing How Product Characteristics Can Streamline Process to Improve Process Simplicity and Reduce COGS” on October 19, 2022, at 12:30 p.m. ET.
Shyam Subramanian, Ph.D., Chief Technical Officer at Obsidian, will present the case study “Driving Manufacturing Process Innovation for Engineering and Expansion of Tumor-Infiltrating Lymphocytes” on October 20, 2022, at 3:00 p.m. ET.
Neoantigen-Based Therapies Summit, October 24-26, 2022, Boston, MA
Jan ter Meulen, M.D., Ph.D., Chief Scientific Officer of Obsidian, will be part of the panel discussion “Engineering Matters to Counter the Tumor Microenvironment (TME) for Better Persistence” on October 25, 2022, at 2:00 p.m. ET.
TIL Therapies Summit, October 24-26, 2022, Boston, MA
Jan ter Meulen, M.D., Ph.D., Chief Scientific Officer of Obsidian, will give the talk “Engineering an IL2-Free, Potent & Persistent TIL With Regulated Membrane-Bound IL15” on October 26, 2022, at 12:30 p.m. ET.
OBX-115 is a novel engineered tumor-infiltrating lymphocyte (TIL) therapy armed with regulated membrane-bound IL15 that is designed to remove the need for concomitant IL2 therapy, a toxic and costly requirement for conventional TILs. OBX-115 preclinical data have demonstrated enhanced TIL persistence, potency and improved tumor control compared to unengineered TILs, which is anticipated to improve clinical outcomes in patients suffering from different types of solid tumors. FDA granted IND clearance for OBX-115 in July 2022. The Phase I FIH clinical trial for OBX-115 is currently recruiting patients. Information regarding the clinical trial is available at clinicaltrials.gov: NCT05470283.
About Obsidian Therapeutics
Obsidian Therapeutics, Inc. is a clinical biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE® technology provides a way to precisely control the timing and level of protein function by using FDA approved small molecules. Obsidian is headquartered in Cambridge, Mass. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. For more information, please visit www.obsidiantx.com and follow us on LinkedIn and Twitter.
Obsidian Therapeutics Media Contact:
Erica Fiorini, Ph.D., or Liz Philips
Russo Partners, LLC
+1 (914) 310-8172